Free Republic

The Food and Drug Administration (FDA) has recently approved an expansion of a respiratory syncytial virus (RSV) vaccine for use in at-risk adults over the age of 50.Manufactured by British multinational pharmaceutical and biotechnology company GSK, this vaccine is the first to be approved for adults aged 50–59, targeting a virus known for causing severe respiratory issues, particularly in older adults and those with pre-existing health conditions.RSV is a common respiratory virus that primarily infects the lungs, nose, throat, and breathing passages. It typically causes mild cold-like symptoms such as a runny nose, fever, cough, and wheezing.“Today’s approval reflects the...

Pfizer failed to inform pregnant women participating in its clinical trial for the respiratory syncytial virus (RSV) vaccine that the clinical trial of a similar vaccine by GlaxoSmithKline (GSK) was halted after a safety signal revealed a potential risk of preterm births leading to neonatal deaths. Even though Pfizer knew about the potential safety signal and was studying preterm births as an “adverse event of special interest,” it continued to enroll women in its clinical trial and did not fully inform participants of the risks the vaccine may pose to their babies—and in some cases, provided misleading and contradictory statements,...

Pharma thinks we need a “vaccine” for every illness, even if it shows up in most people as a mild cold. This latest one has been granted fast-track designation, meaning it will skip the usual scrutiny, just like the covid injections did. Get ready for the fear-mongering so people will roll up their sleeves again.Moderna just moved one step closer to bringing mRNA-1345, an RSV injection, to market. The US Food and Drug Administration (“FDA”) granted the experimental injection fast-track designation in August 2021. Moderna’s mRNA RSV injection has now been given Breakthrough Therapy Designation, which allows for faster development...

Respiratory syncytial virus, usually shortened to RSV, is a common respiratory virus that can cause mild, cold-like symptoms. While most people recover within a couple weeks, the illness can be severe for infants and older adults, sometimes requiring hospitalization. Earlier this year, the CDC approved an RSV vaccine for adults, adding another shot to combat the “tripledemic” we were in last winter between COVID, the flu and RSV. Unlike COVID and the flu, medical professionals are not encouraging everyone to get vaccinated against RSV. In fact, only a handful of the population should get this vaccine. Here’s what to know...

Advisers to the U.S. Food and Drug Administration (FDA) on Thursday recommended, by a vote of 10 to 4, that the agency approve Pfizer’s respiratory syncytial virus (RSV) vaccine for pregnant women, despite questions about the vaccine’s safety. During Thursday’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) meeting, committee members and medical experts raised concerns about premature births identified during Pfizer’s clinical trials. The FDA is expected to issue a final decision on the vaccine in August. If approved, it would become the first RSV vaccine authorized for pregnant women. The Centers for Disease Control and Prevention (CDC) must...

People around the globe have suffered serious adverse reactions resulting from COVID vaccines, especially from the Pfizer shot. Now the Food and Drug Administration (FDA) tells us another Pfizer vaccine can cause serious complications in recipients. After receiving Pfizer’s Respiratory Syncytial Virus (RSV) shot during a clinical trial, two older individuals contracted Guillain-Barré syndrome. This was enough for the FDA to flag the disease as “an important potential risk” from the RSV shot. Yet Pfizer is still seeking approval for general public use. According to the Mayo Clinic, Guillain-Barré syndrome is a rare disorder in which your body’s immune system...